Sangamo Biosciences reported $-43091000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Biogen BIIB:US $ 874.8M 28.6M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
IONIS PHARMACEUT IONS:US $ -103M 39M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Novartis NOVN:VX SF 4129M 217M
Regulus Therapeutics RGLS:US $ -7.26M 0.54M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Sanofi SAN:FP € 2660M 305M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M
Ziopharm Oncology ZIOP:US $ -9.79M 2M